SNOA
Income statement / Annual
Last year (2026), Sonoma Pharmaceuticals Inc.'s total revenue was $19.53 M,
an increase of 36.68% from the previous year.
In 2026, Sonoma Pharmaceuticals Inc.'s net income was -$3.18 M.
See Sonoma Pharmaceuticals Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2026
|
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
03/31/2026 |
03/31/2025 |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
| Operating Revenue |
$19.53 M |
$14.29 M |
$12.74 M |
$13.27 M |
$12.63 M |
$18.63 M |
$17.93 M |
$18.97 M |
$16.66 M |
$12.83 M |
| Cost of Revenue |
$12.11 M
|
$8.82 M
|
$7.99 M
|
$8.80 M
|
$8.64 M
|
$12.07 M
|
$9.81 M
|
$10.09 M
|
$9.35 M
|
$7.16 M
|
| Gross Profit |
$7.42 M
|
$5.47 M
|
$4.75 M
|
$4.48 M
|
$3.99 M
|
$6.56 M
|
$8.12 M
|
$8.88 M
|
$7.31 M
|
$5.67 M
|
| Gross Profit Ratio |
0.38
|
0.38
|
0.37
|
0.34
|
0.32
|
0.35
|
0.45
|
0.47
|
0.44
|
0.44
|
| Research and Development Expenses |
$2.27 M
|
$1.81 M
|
$1.87 M
|
$207.00 K
|
$125.00 K
|
$555.00 K
|
$1.34 M
|
$1.52 M
|
$1.58 M
|
$1.58 M
|
| General & Administrative Expenses |
$0.00
|
$7.17 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$190.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.61 M
|
$7.36 M
|
$7.58 M
|
$8.84 M
|
$9.76 M
|
$9.45 M
|
$14.17 M
|
$18.62 M
|
$19.92 M
|
$17.07 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$9.88 M
|
$9.18 M
|
$9.45 M
|
$9.05 M
|
$9.88 M
|
$10.01 M
|
$15.51 M
|
$20.14 M
|
$21.50 M
|
$18.64 M
|
| Cost And Expenses |
$21.99 M
|
$18.00 M
|
$17.44 M
|
$17.84 M
|
$18.52 M
|
$22.08 M
|
$25.32 M
|
$30.23 M
|
$30.85 M
|
$25.80 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$16.00 K
|
$0.00
|
$16.00 K
|
$50.00 K
|
$190.00 K
|
$258.00 K
|
$22.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$10.00 K
|
$12.00 K
|
$16.00 K
|
$33.00 K
|
$40.00 K
|
$3.00 K
|
| Depreciation & Amortization |
$139.00 K
|
$138.00 K
|
$176.00 K
|
$125.00 K
|
$186.00 K
|
$227.00 K
|
$312.00 K
|
$453.00 K
|
$490.00 K
|
$248.00 K
|
| EBITDA |
-$2.32 M |
-$2.77 M |
-$4.86 M |
-$5.06 M |
-$5.22 M |
-$3.22 M |
-$3.22 M |
-$10.85 M |
-$13.75 M |
-$12.69 M |
| EBITDA Ratio |
-0.12
|
-0.19
|
-0.38
|
-0.38
|
-0.41
|
-0.17
|
-0.18
|
-0.57
|
-0.83
|
-0.99
|
| Operating Income Ratio |
-0.13
|
-0.26
|
-0.37
|
-0.34
|
-0.47
|
-0.19
|
-0.41
|
-0.59
|
-0.85
|
-1.01
|
| Total Other Income/Expenses Net |
-$958.00 K
|
$803.00 K
|
-$330.00 K
|
-$614.00 K
|
$469.00 K
|
-$453.00 K
|
$3.85 M
|
-$82.00 K
|
-$89.00 K
|
$37.00 K
|
| Income Before Tax |
-$3.42 M
|
-$2.91 M
|
-$5.03 M
|
-$5.18 M
|
-$5.42 M
|
-$3.90 M
|
-$3.54 M
|
-$11.34 M
|
-$14.28 M
|
-$12.94 M
|
| Income Before Tax Ratio |
-0.18
|
-0.2
|
-0.4
|
-0.39
|
-0.43
|
-0.21
|
-0.2
|
-0.6
|
-0.86
|
-1.01
|
| Income Tax Expense |
$244.00 K
|
$550.00 K
|
-$196.00 K
|
-$33.00 K
|
-$332.00 K
|
$713.00 K
|
$29.00 K
|
$458.00 K
|
$50.00 K
|
-$4.27 M
|
| Net Income |
-$3.18 M
|
-$3.46 M
|
-$4.84 M
|
-$5.15 M
|
-$5.09 M
|
-$3.95 M
|
-$3.31 M
|
-$11.80 M
|
-$14.33 M
|
$9.27 M
|
| Net Income Ratio |
-0.16
|
-0.24
|
-0.38
|
-0.39
|
-0.4
|
-0.21
|
-0.18
|
-0.62
|
-0.86
|
0.72
|
| EPS |
-1.89 |
-2.79 |
-5.32 |
-15.18 |
-19.17 |
-23.65 |
-22.4 |
-127.6839 |
-284.6619 |
-221.697 |
| EPS Diluted |
-1.89 |
-2.79 |
-5.32 |
-15.18 |
-19.17 |
-23.65 |
-22.4 |
-127.6839 |
-284.6619 |
-221.697 |
| Weighted Average Shares Out |
$1.68 M
|
$1.24 M
|
$909.00 K
|
$339.40 K
|
$265.30 K
|
$199.60 K
|
$147.70 K
|
$92.40 K
|
$50.33 K
|
$46.93 K
|
| Weighted Average Shares Out Diluted |
$1.68 M
|
$1.24 M
|
$909.00 K
|
$339.40 K
|
$265.30 K
|
$199.60 K
|
$147.70 K
|
$92.40 K
|
$50.33 K
|
$46.93 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
